Latest Breaking News On - Gorman subjective diplopia - Page 1 : comparemela.com

Novel anti-IGF-1R antibody promising treatment for Thyroid Eye Disease in clinical trial

An anti-IGF-1R antibody VRDN-001developed by Viridian Therapeutics has succeeded in a phase I/II clinical trial of people with active thyroid eye disease, with participants seeing an average 2.4 mm.

Barrett katzRaymond douglasSinai medical centerThyroid eye disease programViridian therapeuticsClinical activity scoreCedars sinai medical centerActivity dataActivity scoreGorman subjective diplopiaChief medical officerVrdn 001Igf 1rThyroid eye diseaseTed patientsEye disease

Viridian Therapeutics (VRDN) Reports Positive Initial Clinical Data from Ongoing Phase 1/2 Trial Evaluating VRDN-001

Viridian Therapeutics (VRDN) Reports Positive Initial Clinical Data from Ongoing Phase 1/2 Trial Evaluating VRDN-001
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesBarrett katzContactjohn jordanviridian therapeuticsviceRaymond douglasNeither the companySinai medical centerExchange commissionCompany annual report on formThyroid eye disease programViridian therapeutics incInvestor relations corporate communicationsClinical activity scoreCedars sinai medical centerActivity dataallActivity scoreGorman subjective diplopia

Viridian Announces Positive Initial Clinical Data from Ongoing Phase 1/2 Trial Evaluating VRDN-001 in Patients with Thyroid Eye Disease (TED)

Viridian Announces Positive Initial Clinical Data from Ongoing Phase 1/2 Trial Evaluating VRDN-001 in Patients with Thyroid Eye Disease (TED)
forextv.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from forextv.com Daily Mail and Mail on Sunday newspapers.

United statesBarrett katzJohn jordanRaymond douglasNeither the companySinai medical centerCompany annual report on formExchange commissionCorporate communicationsThyroid eye disease programViridian therapeutics incClinical activity scoreViridian therapeuticsCedars sinai medical centerActivity scoreGorman subjective diplopia